Home > Back to Publisher > Report Information

Dyslipidemia: Opportunities in Cardiovascular Risk Reduction

Biophoenix Limited
July 15, 2008
210 Pages - SKU: BPH1870129

Abstract Table of Contents Search inside this report Related Reports

Dyslipidemia: Opportunities in Cardiovascular Risk Reduction

This report examines trends in the $36 billion dyslipidemia market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals. Cholesterol (LDL and HDL) and triglycerides need to be controlled in individuals at risk of developing new or worsening cardiovascular disease (primary and secondary prevention). Antidyslipidemics on the market include statins, ezetimibe, fibrates, niacin products, bile acid sequestrants, and prescription omega-3 products. Many clinical trials over the past 30 years or so have shown that treatment with these drugs substantially reduces cardiovascular risk. The report reviews current approaches to treatment, drugs on the market, marketing strategies, lessons learnt from landmark clinical trials, biomarkers, surrogates of atherosclerosis for drug development, and over 150 products in commercial development. It also derives market forecasts (for the period 2008 to 2012) and assesses market potential.

Why buy this report?

1. gain an insight into the performance of statins and other lipid-modulating drugs and commercial implications of post-marketing clinical trials such as ASTEROID and ENHANCE

2. identify biomarkers and surrogates of atherosclerosis, their potential and limitations in drug development

3. obtain market forecasts for the dyslipidemia market to 2012 by major market segments and geographic areas

4. discover why much of the growth in the dyslipidemia market is forecast to come from non-statin segments, in particular niacins and fibrates

5. be alerted to opportunities presented by the growing challenges of mixed dyslipidemias and undertreated patient subpopulations

6. identify companies developing novel lipid-modulating drugs

7. identify the most promising classes of drugs under development, together with their targets.

Additional Information

Research Methodology

Companies manufacturing or developing products for the treatment of dyslipidemia and atherosclerosis were identified by extensive monitoring of company press releases, industry newsletters, and conference proceedings. Other information in the report was drawn from a wide variety of sources, including the scientific literature, various online databases, academic and company websites, web-based news searches, and company annual reports. Trends in the dyslipidemia market were explored via telephone interviews with senior industry executives.

List of Companies Mentioned

7TM Pharma
Abbott
AbGenomics
Aegerion
Affiris
Alnylam
Amarin
Amgen
Angelini
Arena
Ark Therapeutics
Astellas
AstraZeneca
AtheroGenics
Avanir
Bayer
Bebaas
BioInvent
BioLineRx
Biovitrum
Bristol-Myers Squibb
Celera Genomics
Cerenis
Chipscreen Biosciences
CombinatoRx
Critical Therapeutics
CV Therapeutics
Cytos Biotechnology
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
deCODE genetics
Dr Reddy's Laboratories
Eisai
Elan
Eli Lilly
Exelixis
Ferrer
Forbes Medi-Tech
GalMed Medical Research
Genentech
Genfit
Genzyme
Giaconda
GlaxoSmithKline
GlycoMimetics
Hillcrest Therapeutics
Hollis-Eden Pharmaceuticals
Isis Pharmaceuticals
Japan Tobacco
Johnson & Johnson
Kalypsys
Karo Bio
Kemia
KineMed
Kowa
Kyorin
Lexicon Pharmaceuticals
LifeCycle Pharma
Ligand
Lipid Sciences
Liponex
Martek Biosciences
Merck & Co
Merck KGaA
Metabasis Therapeutics
Metabolex
Metabolic Solutions
Microbia
Millennium
Mitsubishi Tanabe Pharma
Mochida
Napo Pharmaceuticals
NicOx
Nippon Chemiphar
Nippon Shinyaku
Nissan Chemical
Novartis
Numerate
Ono
Orion Pharma
Paladin Labs
Perlecan Pharma
Pfizer
PheneX
Phosphagenics
Pierre Fabre
Plexxikon
Poli
Pronova BioPharma
Protemix
QuatRx
Ranbaxy
ratiopharm
Recordati
Resverlogix
Sanofi-Aventis
Santaris Pharma
Schering-Plough
Sciele Pharma
Scotia Pharmaceuticals
Servier
Shionogi
Solvay
SPA
Surface Logix
Takeda
Targeted Genetics
Teijin
Teva
Theracos
Titan Pharmaceuticals
TransTech Pharma
Vascular Biogenics
VIA Pharmaceuticals
Watson
Wyeth
Yeda
Zydus Cadila

Executive Summary
Chapter 1 Introduction: 1.0 Executive summary; 1.1 Dyslipidemia and atherosclerosis; 1.2 Atherosclerotic vascular diseases; 1.3 Background on lipids and lipoproteins; 1.4 Atherosclerosis; 1.5 Hyperlipidemia; 1.6 Atherogenic dyslipidemia; 1.7 Lipids, CVD risk and treatment goals
Chapter 2 Biomarkers and surrogates of atherosclerosis: 2.0 Executive summary; 2.1 Introduction; 2.2 Vascular imaging technologies; 2.3 Plasma biomarkers
Chapter 3 Improving mainstay therapies: 3.0 Executive summary; 3.1 Introduction; 3.2 Dietary manipulations; 3.3 Statins; 3.4 Cholesterol absorption inhibitors; 3.5 Niacin; 3.6 Fibrates; 3.7 Bile acid sequestrants; 3.8 Combination therapies
Chapter 4 Focus on HDL: 4.0 Executive summary; 4.1 HDL-C levels and cardiovascular risk; 4.2 Background on HDL; 4.3 Current treatments which increase HDL; 4.4 Novel therapies in commercial development
Chapter 5 Other lipid modulators in development: 5.0 Executive summary; 5.1 Introduction; 5.2 PPAR agonists; 5.3 Anti-obesity therapies; 5.4 Thyroid hormone function agonists; 5.5 MTP inhibitors; 5.6 Leukotriene antagonists; 5.7 Succinobucol; 5.8 ApoB inhibitors; 5.9 Kinase modulators; 5.10 Miscellaneous drugs targeting lipid metabolism; 5.11 Miscellaneous drugs targeting inflammation
Chapter 6 Market outlook: 6.0 Executive summary; 6.1 Introduction; 6.2 The broad spectrum of dyslipidemia; 6.3 The dyslipidemia market by therapy; 6.4 Forecasts
Chapter 7 Market potential: 7.0 Executive summary; 7.1 Introduction; 7.2 New therapies; 7.3 Reaching more patients; 7.4 Increasing patient compliance; 7.5 Promoting combination therapies
Appendix 1 Cholesterol Value Reporting
Appendix 2 Abbreviations and Acronyms: A2.1 Scientific/medical terms; A2.2 Institutions; A2.3 Clinical trials
Appendix 3 Research Methodology
List of Tables and Figures: Fig. 1.1 LDL-C and relative risk of CHD; Table 1.1 Findings of the INTERHEART Study; Table 1.2 First presentation of CHD in the UK; Table 1.3 European Society of Cardiology Lipid Guidelines (2003); Table 1.4 European Society of Cardiology Lipid Guidelines (2007); Table 1.5 NCEP ATP III Lipid Goals and Cut-Points (2001); Table 1.6 Revised NCEP ATP III Lipid Goals and Cut-Points (2004); Table 1.7 Classification of fasting triglyceride levels in adults; Table 1.8 Metabolic Syndrome Criteria; Table 1.9 Therapeutic goals for LDL-C and potential goals for non-HDL-C and total apo B; Table 2.1 LDL-C and atheroma volume in several IVUS trials; Table 2.2 Ongoing Clinical Trials in Dyslipidemia Using a CIMT Endpoint; Table 2.3 Ongoing Clinical Trials in Dyslipidemia Using an IVUS Endpoint; Table 2.4 Ongoing Clinical Trials in Dyslipidemia Using Lp(a) as an Endpoint; Table 2.5 Ongoing Clinical Trials in Dyslipidemia Using Oxidized DL as an Endpoint; Table 2.6 Ongoing Clinical Trials in Dyslipidemia Using CRP as an Endpoint; Fig. 3.1 Relative LDL Lowering Potencies of Five Marketed Statins; Table 3.1 Some Landmark Trials in Dyslipidemia; Table 3.2 Patent Data for Launched Statin Products; Table 3.3 Suppliers of Off-Patent and Near Off-Patent Statins; Table 3.4 Crestor Trial Programme (GALAXY); Table 3.5 Fixed Dose Combination Products On The Market Or In Development; Table 3.6 Ongoing Clinical Trials in Dyslipidemia Using Statin/Ezetimibe Combinations; Table 3.7 Ongoing Clinical Trials in Dyslipidemia Using Niacin Combinations; Table 3.8 Ongoing Clinical Trials in Dyslipidemia Using Statin/Fibrate and Other Statin Combinations; Table 3.9 Other Ongoing Clinical Trials in Dyslipidemia Using Combined Agents; Table 4.1 At-a-glance guide to experimental therapies which may boost HDL levels and/or function; Table 5.1 At-a-glance guide to experimental therapies targeting lipid metabolism and/or inflammation; Table 5.2 Ongoing Clinical Trials in Hypertriglyceridemia; Table 6.1 Worldwide Sales of Branded Statins in 2007; Table 6.2 Worldwide Sales of Branded Non-Statin Antidyslipidemics in 2007; Table 6.3 Statin Sales Analysis and Forecasts, 2007-2012; Table 6.4 Statin Prescription Analysis and Forecasts, 2007-2012; Table 6.5 Dyslipidemia Market by Drug Class, 2007-2012; Table 6.6 Dyslipidemia Market by Prescriptions, 2007-2012; Table 6.7 Dyslipidemia Market by Country, 2007-2012; Table 7.1 Cancer and Cardiovascular Pipelines by Type of Agent; Table 7.2 Dyslipidemia Market by Patient Numbers, 2007-2012; Table 7.3 Ongoing Clinical Trials in Metabolic Syndrome

Dyslipidemia: Opportunities in Cardiovascular Risk Reduction

Share this report

Other tasks

Research Assistance

Related Markets

Cardiovascular Reports

Free Alert Me service